Evolus, Inc. (EOLS)

7.14 -0.55 (-7.15%) USD  |  NASDAQ  |  Oct 02, 16:00
7.135 0.00 (0.00%) After-Hours: 20:00
More

Evolus EPS Diluted (Quarterly) : -0.1221 for June 30, 2026

EPS Diluted (Quarterly) Chart

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 -0.1221
March 31, 2026 -0.1638
December 31, 2025 0.002
September 30, 2025 -0.2431
June 30, 2025 -0.2656
March 31, 2025 -0.2966
December 31, 2024 -0.1072
September 30, 2024 -0.3036
June 30, 2024 -0.181
March 31, 2024 -0.223
December 31, 2023 -0.2067
September 30, 2023 -0.2968
June 30, 2023 -0.3187
March 31, 2023 -0.2619
December 31, 2022 -0.234
September 30, 2022 -0.3609
June 30, 2022 -0.4185
March 31, 2022 -0.314
December 31, 2021 -0.3271
September 30, 2021 -0.3533
Date Value
June 30, 2021 -0.305
March 31, 2021 0.1557
December 31, 2020 -3.280
September 30, 2020 -0.3395
June 30, 2020 -0.6262
March 31, 2020 -0.5853
December 31, 2019 -0.4724
September 30, 2019 -0.9823
June 30, 2019 -1.371
March 31, 2019 -0.4016
December 31, 2018 -0.4553
September 30, 2018 -0.4776
June 30, 2018 -0.69
March 31, 2018 -0.3046
December 31, 2017 0.24
September 30, 2017 -0.1082
June 30, 2017 -0.14
March 31, 2017 -0.1691
December 31, 2016 -0.1538

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 1.052
Corcept Therapeutics, Inc. 0.356
Veru, Inc. -0.3032
Johnson & Johnson 2.268
Eli Lilly & Co. 7.939

EPS Diluted (Quarterly) Related Metrics

Net Income (Quarterly) -8.052M
Revenue (Quarterly) 84.08M
Total Expenses (Quarterly) 92.14M
Enterprise Value 590.97M
Gross Profit Margin (Quarterly) 66.18%
Profit Margin (Quarterly) -9.58%
Earnings Yield -7.38%
Normalized Earnings Yield -7.672